Director Prof. Pierfrancesco Tassone
Phase I Clinical Trials Center, activated in 2017, it is a structure that allows innovative active principles to be tested on humans for the first time, in order to evaluate their safety and tolerability. In particular, this is an opportunity for cancer patients who do not have valid therapeutic alternatives, due to disease progression or lack of tolerability.